Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:37:31.535Z.
Calculation as of: 2026-10-06T15:37:31.535Z.
Quote observation: 2026-10-06T15:34:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c1ebec02882b5d134f555e456bf3ec52d4d7fba3d3c39a772b469d051cfe6f8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.55M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $26.75M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.62M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $25.57M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.59M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.78M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.95M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.00M | N/A | 392.49% | 233.09% | 233.09% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.83M | N/A | 0.01% | 0.01% | 0.01% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute